Neuren Pharmaceuticals Limited (NEU) is a biopharmaceutical firm dedicated to advancing therapies for brain injury, neurodevelopmental, and neurodegenerative disorders. At the forefront of their research are two pivotal drug products: NNZ-2566 and NNZ-2591. Operating across New Zealand, Australia, and the USA, NEU is strategically positioned to drive forward its mission of developing effective treatments that address critical neurological conditions on a global scale.